search
Back to results

Adjunctive Ivermectin Mass Drug Administration for Malaria Control (MATAMAL)

Primary Purpose

Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis

Status
Recruiting
Phase
Phase 3
Locations
Guinea-Bissau
Study Type
Interventional
Intervention
Ivermectin
Placebo
Dihydroartemisinin-piperaquine
Sponsored by
London School of Hygiene and Tropical Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malaria,Falciparum focused on measuring Vector Control, Mass Drug Administration, Integrated Disease Control, Malaria, Guinea Bissau, West Africa, Antimalarials, Ivermectin, Dihydroartemisinin, Piperaquine

Eligibility Criteria

6 Months - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age over six months to receive dihydroartemisinin-piperaquine
  2. Height over 90cm or weight over 15kg to receive ivermectin or placebo
  3. Willingness to adhere to trial procedures
  4. Individual written, informed consent from the participant or parent/guardian in the case of participants below the age of 18 years (and assent in young people between the ages of 12 and 17 years of age)

Exclusion Criteria:

  1. Known severe chronic illness (AIDS, Tuberculosis, chronic malnutrition)
  2. Known hypersensitivity to either dihydroartemisinin-piperaquine or ivermectin
  3. Pregnancy (any trimester) and breastfeeding (for ivermectin (or placebo)) and pregnancy (first trimester only) (for dihydroartemisinin-piperaquine)
  4. Travel to a Loa loa endemic country (eg Central African Republic) (for ivermectin (or placebo))
  5. Concomitant drugs that influence cardiac function or affect the corrected QT interval (for dihydroartemisinin-piperaquine)

Sites / Locations

  • Bijagos Archipelago (islands)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ivermectin Mass Drug Administration

Placebo Mass Drug Administration

Arm Description

Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.

Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.

Outcomes

Primary Outcome Measures

Prevalence of infection with Plasmodium falciparum
Prevalence of infection with Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample conducted during peak transmission season after 2 years of intervention

Secondary Outcome Measures

Vector parous rate
Vector parous rate will be determined by assessment of mosquitoes trapped 7-14 days following MDA. Vector parity will be used to determine Anopheles gambiae age structure to estimate vector survival between arms.
Prevalence of infection with Plasmodium falciparum
Prevalence of infection with Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample conducted after the first year of intervention
Incidence of clinical malaria (Passive Case Detection)
Incidence of clinical malaria diagnosed at health facilities confirmed by malaria Rapid Diagnostic Test
Incidence of clinical malaria (Active Case Detection)
Incidence of clinical malaria confirmed by malaria Rapid Diagnostic Test in a cohort of 50 children per cluster aged 5-14 years
Age-adjusted prevalence of recent exposure to Plasmodium falciparum
Mean Median Fluorescence Intensity of serological markers associated with recent exposure to Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample during peak transmission season after each year of intervention
Vector density
Total number of trapped mosquitoes per cluster
Vector species composition
Species characterisation using nucleic acid amplification tests as a proportion of total mosquitoes caught in traps
Prevalence of exposure to Anopheles exposure
Mean Median Fluorescence Intensity of serological markers associated with exposure to Anopheles salivary antigen in all age groups estimated using a cross-sectional survey sample
Vector sporozoite rates
Proportion of Plasmodium falciparum circumsporozoite antibody (CSP) positive mosquitoes caught in traps
Prevalence of Ivermectin-susceptible Neglected Tropical Diseases (NTDs)
Prevalence of IVM-susceptible NTDs (scabies, strongyloides, other soil-transmitted helminths and lymphatic filariasis) and head lice using clinical and serological parameters estimated using a cross-sectional survey sample during the dry season after two years of intervention.
MDA coverage estimates
Cluster level coverage estimates calculated from MDA distribution and denominator census
Prevalence of resistance to artemisinin and partner drugs in humans
Prevalence of resistance to artemisinin and partner drugs in humans using molecular markers of resistance in all age groups estimated using a cross-sectional survey sample

Full Information

First Posted
March 17, 2021
Last Updated
February 22, 2022
Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Medical Research Council Unit, The Gambia, Ministerio de Saude Publica, Guinee-Bissau, Bandim Health Project, Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau
search

1. Study Identification

Unique Protocol Identification Number
NCT04844905
Brief Title
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
Acronym
MATAMAL
Official Title
Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 3, 2021 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
August 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Medical Research Council Unit, The Gambia, Ministerio de Saude Publica, Guinee-Bissau, Bandim Health Project, Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a cluster-randomized placebo-controlled clinical trial to evaluate the additive benefit of Ivermectin (IVM) (or Placebo) mass drug administration (MDA) to dihydroartemisinin-piperaquine (DP) MDA for malaria control in a moderate to low malaria-endemic setting as an adjunctive strategy to existing programmatic malaria control measures. The regime of DP and IVM will target both human reservoirs of Plasmodium falciparum and the Anopheles gambiae vector respectively, with the aim of interrupting transmission. The trial will be conducted on the Bijagos Archipelago, where islands (clusters) will be randomised to receive seasonal DP and IVM or DP and Placebo MDA. The primary outcome will be the prevalence of infection with Plasmodium falciparum in all age groups detected by nucleic acid amplification testing during the peak malaria transmission season after two years of intervention.
Detailed Description
The objectives of this trial are To evaluate the impact of adjunctive IVM to DP MDA on malaria transmission in communities with high ITN coverage. To evaluate the impact of IVM MDA on An. gambiae population density and age-structure. To evaluate the impact of IVM MDA on the prevalence of co-endemic IVM-susceptible Neglected Tropical Diseases (lymphatic filariasis, soil transmitted helminths and scabies) To evaluate acceptability, feasibility and access to MDA as a strategy for malaria control and to identify the most acceptable way of achieving and sustaining high coverage MDA with IVM and DP. This cluster-randomized placebo-controlled trial has two arms. A total of 24 clusters will be randomly assigned to receive DP + IVM MDA or DP+ Placebo MDA using computer-generated random numbers. To mitigate against contamination effects, the majority of clusters will be separate islands and will be separated by distances greater than 2km. On the two islands that are divided (each into two clusters), a buffer zone of 2km between each cluster will be ensured. The total population of the archipelago is 24,000. The investigators will ensure balance between trial arms with respect to population size, baseline Plasmodium falciparum prevalence and access to health care. All clusters will receive the standard programmatic malaria control interventions implemented by the National Malaria Control Programme which includes insecticide-treated nets (ITN), intermittent preventative treatment in pregnancy (IPTp), seasonal malarial chemoprophylaxis (SMC) for children aged 3-59 months and case diagnosis and treatment (CDT) with Artemether-lumefantrine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis, Lymphatic Filariasis, Scabies, Hook Worm, Soil Transmitted Helminths
Keywords
Vector Control, Mass Drug Administration, Integrated Disease Control, Malaria, Guinea Bissau, West Africa, Antimalarials, Ivermectin, Dihydroartemisinin, Piperaquine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Two arms with clusters randomized to DP+IVM or DP+Placebo with a 1:1 ratio
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
An independent statistician will randomize the clusters to DP+IVM or DP+Placebo. The Placebo is identical in size, shape and colour and packaging. An independent pharmacist at Medical Research Council Unit The Gambia @ London School of Hygiene and Tropical Medicine will label the IVM and Placebo according to the statistician's designation and maintain the masking from all other investigators. Specifically generated masking codes will be generated and saved in three separate encrypted locations securely. Only the statistician and the pharmacist will have access to the encryption key.
Allocation
Randomized
Enrollment
24000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ivermectin Mass Drug Administration
Arm Type
Experimental
Arm Description
Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
Arm Title
Placebo Mass Drug Administration
Arm Type
Placebo Comparator
Arm Description
Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
Intervention Type
Drug
Intervention Name(s)
Ivermectin
Intervention Description
Ivermectin will be given as tablets of 3 or 6mg. It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken on an empty stomach with water.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
Intervention Type
Drug
Intervention Name(s)
Dihydroartemisinin-piperaquine
Other Intervention Name(s)
Eurartesim
Intervention Description
Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
Primary Outcome Measure Information:
Title
Prevalence of infection with Plasmodium falciparum
Description
Prevalence of infection with Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample conducted during peak transmission season after 2 years of intervention
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Vector parous rate
Description
Vector parous rate will be determined by assessment of mosquitoes trapped 7-14 days following MDA. Vector parity will be used to determine Anopheles gambiae age structure to estimate vector survival between arms.
Time Frame
7-14 days post-MDA
Title
Prevalence of infection with Plasmodium falciparum
Description
Prevalence of infection with Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample conducted after the first year of intervention
Time Frame
1 year
Title
Incidence of clinical malaria (Passive Case Detection)
Description
Incidence of clinical malaria diagnosed at health facilities confirmed by malaria Rapid Diagnostic Test
Time Frame
For six months during the malaria transmission season
Title
Incidence of clinical malaria (Active Case Detection)
Description
Incidence of clinical malaria confirmed by malaria Rapid Diagnostic Test in a cohort of 50 children per cluster aged 5-14 years
Time Frame
For six months during the malaria transmission season
Title
Age-adjusted prevalence of recent exposure to Plasmodium falciparum
Description
Mean Median Fluorescence Intensity of serological markers associated with recent exposure to Plasmodium falciparum in all age groups estimated using a cross-sectional survey sample during peak transmission season after each year of intervention
Time Frame
Peak transmission season at 1 year and 2 years
Title
Vector density
Description
Total number of trapped mosquitoes per cluster
Time Frame
For six months during the malaria transmission season
Title
Vector species composition
Description
Species characterisation using nucleic acid amplification tests as a proportion of total mosquitoes caught in traps
Time Frame
For six months during the malaria transmission season
Title
Prevalence of exposure to Anopheles exposure
Description
Mean Median Fluorescence Intensity of serological markers associated with exposure to Anopheles salivary antigen in all age groups estimated using a cross-sectional survey sample
Time Frame
Peak transmission season at 1 year and 2 years
Title
Vector sporozoite rates
Description
Proportion of Plasmodium falciparum circumsporozoite antibody (CSP) positive mosquitoes caught in traps
Time Frame
For six months during the malaria transmission season
Title
Prevalence of Ivermectin-susceptible Neglected Tropical Diseases (NTDs)
Description
Prevalence of IVM-susceptible NTDs (scabies, strongyloides, other soil-transmitted helminths and lymphatic filariasis) and head lice using clinical and serological parameters estimated using a cross-sectional survey sample during the dry season after two years of intervention.
Time Frame
2 years
Title
MDA coverage estimates
Description
Cluster level coverage estimates calculated from MDA distribution and denominator census
Time Frame
During MDA in year 1 and year 2
Title
Prevalence of resistance to artemisinin and partner drugs in humans
Description
Prevalence of resistance to artemisinin and partner drugs in humans using molecular markers of resistance in all age groups estimated using a cross-sectional survey sample
Time Frame
Peak transmission season at 1 year and at 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age over six months to receive dihydroartemisinin-piperaquine Height over 90cm or weight over 15kg to receive ivermectin or placebo Willingness to adhere to trial procedures Individual written, informed consent from the participant or parent/guardian in the case of participants below the age of 18 years (and assent in young people between the ages of 12 and 17 years of age) Exclusion Criteria: Known severe chronic illness (AIDS, Tuberculosis, chronic malnutrition) Known hypersensitivity to either dihydroartemisinin-piperaquine or ivermectin Pregnancy (any trimester) and breastfeeding (for ivermectin (or placebo)) and pregnancy (first trimester only) (for dihydroartemisinin-piperaquine) Travel to a Loa loa endemic country (eg Central African Republic) (for ivermectin (or placebo)) Concomitant drugs that influence cardiac function or affect the corrected QT interval (for dihydroartemisinin-piperaquine)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna R Last, MBChB PhD
Phone
0044(0)2072770
Ext
2770
Email
anna.last@lshtm.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
David CW Mabey
Email
david.mabey@lshtm.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna R Last, MBChB PhD
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bijagos Archipelago (islands)
City
Bissau
Country
Guinea-Bissau
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amabelia Rodrigues, PhD
Email
a.rodrigues@bandim.org
First Name & Middle Initial & Last Name & Degree
Harry Hutchins, MBChB
Email
harry.hutchins@lshtm.ac.uk
First Name & Middle Initial & Last Name & Degree
Amabelia Rodrigues, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
There is a manuscript in preparation detailing the study protocol and statistical analysis plan. The participant information and and informed consent form may be requested from the trial research team. Results and a clinical study report will be made available within six months of completion of the trial. Analytic code will be made available under a Creative Commons license. Publication of results will be open-access and available in pre-print on MedRxiv (The Preprint Server for Health Sciences).
IPD Sharing Time Frame
The study protocol and Statistical Analysis Plan (SAP) will be made available on acceptance of the manuscript for publication. Participant information and Informed Consent Form (ICF) will be made available from recruitment. Results (including Clinical Study Report (CSR)) will be made available within six months of completion of the trial.
IPD Sharing Access Criteria
Study Protocol and Statistical Analysis Plan (SAP) will be published in an Open Access peer-reviewed journal. The participant information and and informed consent form may be requested from the trial research team. Results and a clinical study report will be made available within six months of completion of the trial. Analytic code will be made available under a Creative Commons license. Publication of results will be Open-Access and available in pre-print on MedRxiv (The Preprint Server for Health Sciences).

Learn more about this trial

Adjunctive Ivermectin Mass Drug Administration for Malaria Control

We'll reach out to this number within 24 hrs